Related Experiment Video
Updated: Aug 30, 2026
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
Liposomal amphotericin B treatment for rhinocerebral mucormycosis: how much is enough?
Ophir Handzel1, Zvi Landau, Doron Halperin
1Department of ENT/Head and Neck Surgery, Hebrew University, Hadassah School of Medicine, Jerusalem, Israel. handzel@clalit.org.il
Abstract:
Rhinocerebral Mucormycosis is a potentially life-threatening disease, which affects mainly immunocompromised patients. Treatment options include reversing immunosuppression, surgery and systemic and local administration of anti-fungal medication. Amphotericin B is the primary agent employed, but its use is often limited by frequent side effects. Complexing Amphotericin B with lipid structures avoids most of the negative side effects, most importantly the dose-limiting nephrotoxicity. No consensus has been reached regarding the appropriate duration, rate of administration or total dose of treatment. We present a case of a patient suffering from Rhinocerebral Mucormycosis treated by extensive surgery and Liposomal Amphotericin B. He was treated for 29 days at a rate of 3 mg/kg/d and a total dose of 5.6 gram. The dose of Liposomal Aphotericin B used in previously published articles ranged from 1.5 mg/kg/d to 5 mg/kg/d. The response to treatment may be evaluated by physical examination, microbiological cultures, radiological and pathological studies. Taking into account the considerable cost of liposomal Amphotericin B and other lipid complexed formulations, it is imperative to find out what is the appropriate treatment regime for Rhinocerebral and other mucormycosis infections.
Insights
Rhinocerebral mucormycosis, a serious fungal infection, requires effective treatment. This case study explores Liposomal Amphotericin B as a treatment option for immunocompromised patients, highlighting its administration and outcomes.
Area of Science:
- Mycology
- Infectious Diseases
- Medical Mycology
Background:
- Rhinocerebral mucormycosis is a severe, life-threatening fungal infection primarily affecting immunocompromised individuals.
- Current treatments include immunosuppression reversal, surgery, and antifungal medications, with Amphotericin B being a primary agent.
- Amphotericin B's utility is limited by significant side effects, particularly nephrotoxicity, which lipid formulations aim to mitigate.
Observation:
- A case of Rhinocerebral Mucormycosis in an immunocompromised patient treated with extensive surgery and Liposomal Amphotericin B is presented.
- The patient received Liposomal Amphotericin B at 3 mg/kg/d for 29 days, totaling 5.6 grams.
- Published literature indicates Liposomal Amphotericin B doses ranging from 1.5 mg/kg/d to 5 mg/kg/d for mucormycosis.
Findings:
- Liposomal Amphotericin B, when used with surgery, demonstrated a potential treatment approach for Rhinocerebral Mucormycosis.
- Treatment response can be monitored through clinical examination, cultures, and imaging studies.
- The specific dosage and duration of Liposomal Amphotericin B require further investigation to establish optimal therapeutic regimens.
Implications:
- Establishing optimal treatment regimens for Rhinocerebral Mucormycosis is crucial, considering the high cost of lipid-based Amphotericin B formulations.
- Further research is needed to determine the ideal dose, rate of administration, and total dose for Liposomal Amphotericin B in treating mucormycosis.
- This case contributes to understanding the management of this rare but devastating infection.
Related Concept Videos
01:15Antifungal Agents
01:27Cryptococcal Meningitis